65,395 CG Oncology, Inc. $CGON Shares Bought by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. increased its holdings in shares of CG Oncology, Inc. (NASDAQ:CGON) by 8.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 835,342 shares of the company’s stock after acquiring an additional 65,395 shares during the period. CG Oncology comprises about 0.4% of Jefferies Financial Group Inc.’s investment portfolio, making the stock its 24th biggest position. Jefferies Financial Group Inc. owned 0.94% of CG Oncology worth $59,217,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in CG Oncology in the second quarter worth about $444,509,000. Bank of America Corp DE bought a new position in CG Oncology during the second quarter worth about $69,978,000. Seven Fleet Capital Management LP lifted its stake in CG Oncology by 24.5% during the second quarter. Seven Fleet Capital Management LP now owns 1,886,236 shares of the company’s stock worth $134,017,000 after purchasing an additional 371,085 shares during the period. Bank of New York Mellon Corp acquired a new stake in CG Oncology during the second quarter valued at approximately $16,584,000. Finally, TimesSquare Capital Management LLC acquired a new stake in CG Oncology during the second quarter valued at approximately $14,983,000. Institutional investors own 26.56% of the company’s stock.

Key CG Oncology News

Here’s some of the latest news about CGON:

• Positive Sentiment: CG Oncology’s third-quarter loss was narrower than analysts expected, and revenue exceeded estimates. HC Wainwright also maintained a Buy rating and a $100 price target, raising its FY2026 and Q4 2026 earnings forecasts. What CG Oncology’s Third Quarter Earnings Means For Shareholders
• Negative Sentiment: Guggenheim cut its price target for CG Oncology, a potentially bearish analyst signal; the available report does not specify the revised target. CG Oncology Stock Price Target Cut by Guggenheim
• Negative Sentiment: HC Wainwright lowered its earnings forecasts for FY2027, FY2028 and FY2030, suggesting it expects a slower path to profitability farther out, although it kept its Buy rating and $100 target.

CG Oncology Stock Down 0.0%

Shares of CG Oncology stock opened at $72.61 on Thursday. The stock has a market capitalization of $6.49 billion, a P/E ratio of -26.31 and a beta of 0.35. The company has a 50-day simple moving average of $68.13 and a 200 day simple moving average of $66.36. CG Oncology, Inc. has a 12-month low of $37.01 and a 12-month high of $80.97.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings results on Friday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.19. The firm had revenue of $1.60 million during the quarter, compared to the consensus estimate of $0.55 million. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.58%. On average, equities analysts anticipate that CG Oncology, Inc. will post -3.03 earnings per share for the current year.

Insider Activity

In other news, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $62.06, for a total value of $62,060.00. Following the completion of the transaction, the director owned 1,000 shares in the company, valued at approximately $62,060. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 3,000 shares of company stock valued at $209,580 in the last three months. Insiders own 4.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on CGON shares. Wall Street Zen upgraded CG Oncology from a “strong sell” rating to a “sell” rating in a research note on Saturday, November 7th. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of CG Oncology in a research report on Wednesday, July 29th. Piper Sandler boosted their price target on CG Oncology from $82.00 to $85.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Royal Bank Of Canada lowered their price target on CG Oncology from $81.00 to $79.00 and set an “outperform” rating on the stock in a research report on Friday, August 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a research report on Thursday, October 15th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $88.11.

CG Oncology Company Profile

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.